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Abstract
In this study, we investigated whether local intramyocardial GATA4 overexpression 
affects the left ventricular (LV) remodelling process and the importance of phospho-
rylation at serine 105 (S105) for the actions of GATA4 in an angiotensin II (AngII)-
induced hypertension rat model. Adenoviral constructs overexpressing wild-type 
GATA4 or GATA4 mutated at S105 were delivered into the anterior LV free wall. 
AngII (33.3 µg/kg/h) was administered via subcutaneously implanted minipumps. 
Cardiac function and structure were examined by echocardiography, followed by 
histological immunostainings of LV sections and gene expression measurements by 
RT-qPCR. The effects of GATA4 on cultured neonatal rat ventricular fibroblasts 
were evaluated. In AngII-induced hypertension, GATA4 overexpression repressed 
fibrotic gene expression, reversed the hypertrophic adult-to-foetal isoform switch 
of myofibrillar genes and prevented apoptosis, whereas histological fibrosis was not 
affected. Overexpression of GATA4 mutated at S105 resulted in LV chamber dilata-
tion, cardiac dysfunction and had minor effects on expression of myocardial remod-
elling genes. Fibrotic gene expression in cardiac fibroblasts was differently affected 
by overexpression of wild-type or mutated GATA4. Our results indicate that GATA4 
reduces AngII-induced responses by interfering with pro-fibrotic and hypertrophic 
gene expressions. GATA4 actions on LV remodelling and fibroblasts are dependent 
on phosphorylation site S105.
K E Y W O R D S
angiotensin II, fibrosis, hypertension, myocardial remodelling, transcription factor
   | 179JURADO ACOSTA eT Al.
1 |  INTRODUCTION
Cardiovascular diseases are the prevalent cause of mortality 
in Europe 1 and the United States,2 and high blood pressure is 
the strongest risk factor for cardiovascular diseases and heart 
failure.1,2 Cardiac remodelling secondary to pressure over-
load and ischaemic injury is attributed to mechanical stress 
and to neuroendocrine and local factors, such as angioten-
sin II (AngII), catecholamines, aldosterone and transforming 
growth factor-β (TGFβ).3-6 Pathological myocardial remod-
elling is characterized by excessive extracellular matrix 
(ECM) deposition along with hypertrophic growth of car-
diomyocytes (CMs).7-10 Cardiac fibroblasts (CFs) maintain a 
quiescent phenotype under physiological conditions and can 
be activated in response to various types of cardiac stress, 
becoming the drivers of ECM remodelling and the fibrotic 
response.6,9 Initially, ECM remodelling acts to preserve heart 
function and integrity, although it can gradually become ex-
cessive and maladaptive, progressing into cardiac dysfunc-
tion and heart failure.7-10
A hallmark of hypertension is overstimulation of the re-
nin-angiotensin system (RAS) through AngII/AngII type 1 
receptor (AT1-R) axis, resulting in augmented blood pres-
sure and elevated vascular/interstitial fibrosis. AngII induces 
hypertrophic growth in CMs and hyperplasia in CFs through 
distinct AT1-R-associated pathway activation.3,11 It is now 
well-established that AngII/AT1-R activation mediates organ 
fibrosis and promotes TGFβ1 expression.3-5,12 In agreement 
with this view, studies conducted in animal models of hy-
pertension have shown that AngII/AT1-R-elicited fibrosis is 
suppressed by treatment with AT1-R blockers.13-15 Moreover, 
AT1-R blockers losartan and telmisartan have been demon-
strated to reduce macrophage infiltration and CF trans-
differentiation to myofibroblasts (MF) through inhibiting 
AngII- and TGFβ-induced phosphorylation of extracellular 
signal-regulated kinase-1/2 (ERK1/2).12,16 Pharmacological 
interventions with angiotensin converting enzyme (ACE) 
inhibitors or AT1-R blockers have also been shown to ef-
ficiently limit the progression of heart failure through re-
gressing fibrosis, underscoring the relevance of AngII in the 
development of cardiac fibrosis. Even though the pro-fibrotic 
effects of AngII have been extensively reported, the molec-
ular mechanisms for AngII-induced myocardial remodelling 
and fibrosis have not been fully elucidated.
The zinc finger transcription factor GATA4 is essential for 
cardiac development and plays a critical role in the growth 
and survival response of CMs.17-19 Interestingly, GATA4 
activity is enhanced under cardiac stress 20-22 through phos-
phorylation at serine 105 (S105) residue by ERK1/2 and p38 
mitogen-activated protein kinases (MAPKs) acting down-
stream of AT1-R.17,19,23,24 Studies on loss of GATA4 activ-
ity have highlighted its importance for cardiac remodelling, 
including the hypertrophic and fibrotic responses to stress in 
the adult hearts.25,26 Most of the studies involving the actions 
of GATA4 in adult heart have focused on hypertrophic cell 
growth and survival pathways in CMs, even though GATA4 
is expressed also in CFs and pericytes,27 and has been sug-
gested to repress fibrosis through down-regulation of tran-
scriptional regulator Snai1.28 However, the role of GATA4 
in mediating the fibrotic response to cardiac stress and its 
function in cardiac fibroblasts remain poorly understood. 
In the present study, we investigated whether GATA4 over-
expression influences the left ventricular (LV) remodelling 
process and fibrosis in response to AngII. Furthermore, we 
studied the role of phosphorylation site S105 for the actions 
of GATA4 in the adult heart during the cardiac stress in ex-
perimental models of AngII-induced hypertension and myo-
cardial infarction (MI) in rats.
2 |  MATERIALS AND METHODS
2.1 | Animal models
Male 2-month-old Sprague Dawley rats (250 to 300 g) were 
obtained from the colony of the Center of Experimental 
Animals at the University of Oulu, Finland. All animal proce-
dures were approved by the Animal Use and Care Committee 
of the University of Oulu and the Provincial Government of 
Southern Finland Department of Social Affairs and Health 
and conform to the guidelines from Directive 2010/63/EU of 
the European Parliament on the protection of animals used 
for scientific purposes. The study was conducted in accord-
ance with the Basic & Clinical Pharmacology & Toxicology 
policy for experimental and clinical studies.29
2.2 | Angiotensin II-induced hypertension, 
myocardial infarction and adenoviral 
gene transfer
The rats were anaesthetized, and operations were performed 
as previously described.30,31 AngII (33.3  µg/kg/h) was ad-
ministered via the subcutaneously implanted minipumps 
(Alzet model 2002, DURECT Corporation, Cupertino, CA, 
USA) for one and two weeks.31,32 In this model of experi-
mental hypertension, administration of AngII increases mean 
arterial pressure within 3 hour and remains significantly el-
evated throughout the two-week follow-up period.31 In addi-
tion to the increased ventricular wall loading subsequent to 
hypertension, AngII infusion also induces CM hypertrophic 
growth via direct AT1-R activation.3,4
In a separate series of experiments, the left anterior descend-
ing coronary artery (LAD) was permanently ligated to gener-
ate experimental MI following adenoviral gene transfer into rat 
hearts.30 The sham-operated rats underwent the same surgical 
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procedure without LAD ligation. The animals were followed 
for three days, and one and two weeks after the intervention.
For gain-of-function studies, adenovirus type 1 (Ad1) 
containing the GATA4 coding region 17 or recombinant repli-
cation-deficient type 5 adenovirus (Ad5) containing GATA4-
S105A mutated construct 18 (1 × 109 pfu and 2 × 109 pfu, 
respectively, in 100 µL) were injected directly into the LV an-
terior wall following AngII minipump implantation or sham/
LAD ligation intervention within the same surgical proce-
dure. A precision Hamilton syringe was inserted intramurally 
(apex to base direction) at one site and slowly withdrawn 
while releasing the adenovirus solution.33 Ad5 expressing 
nuclear localization signal (nls)—β-lactosidase LacZ, was 
used as control constructs (at Ad1-GATA4 or Ad5-GATA4-
S105A experiments in matched doses) and underwent the 
same administration procedure. After the operations, anaes-
thesia was partially antagonized with atipamezole hydro-
chloride (Antisedan, 1.5  mg/kg, intraperitoneal (i.p.)) and 
rats were hydrated with physiological saline solution (5 mL, 
subcutaneous (s.c.)). For postoperative analgesia, buprenor-
phine hydrochloride (Vetergesic, 0.05-0.2  mg/kg, s.c.) was 
administered. Figure 1 depicts the timelines for the different 
treatments and measurements performed in both experimen-
tal animal models here used.
2.3 | Echocardiography
At the end of the experiments, transthoracic echocardiog-
raphy was performed with the Vevo2100 high-frequency 
F I G U R E  1  Timeline for the in vivo experiments. (A) Angiotensin II-induced hypertension. Rats were implanted with osmotic minipumps 
loaded with AngII (33.3 µg/kg/h) and adenoviral constructs overexpressing GATA4 or GATA4-S105A (1 × 109 pfu and 2 × 109 pfu, respectively, 
in 100 µL) or dose-matched LacZ adenoviral constructs were injected into the LV anterior free wall, generating four adenovirus treatment groups 
followed for 7 and 14 d. (b) Myocardial infarction. LAD ligation or a sham intervention was performed in rats at day 0, followed by injection of 
adenoviral constructs overexpressing GATA4-S105A (2 × 109 pfu in 100 µL) or dose-matched LacZ adenoviral constructs within the same surgical 
procedure. Due to different virus dose, the control LacZ groups are not comparable to each other. The groups were studied at 3, 7 or 14 d. At the 
end of experiments, the cardiac function and structure were analysed by echocardiography and the hearts were excised and processed for further 
histological and biochemical analyses
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high-resolution linear array ultrasound system (FujiFilm 
VisualSonics Inc, Toronto, Canada) and MS-250 transducer 
(13-24 MHz, axial resolution 75 µm, lateral resolution 165 
µm) under ketamine (50 mg/kg, i.p.) and xylazine (10 mg/
kg, i.p.) anaesthesia, as described previously.33 Morphology 
of the LV, and  systolic and diastolic functions were meas-
ured from the two-dimensional imaging M-mode recordings. 
After echocardiography, the animals were killed and the 
hearts were excised and processed for histologic and bio-
chemical analysis.
2.4 | Histology
The apical transversal mid-section of the heart was fixed in 
10% buffered formalin solution and then embedded in paraf-
fin. Five µm sections were deparaffinized in xylene and de-
hydrated in graded ethanol series and specifically stained as 
described below. The fibrotic tissue in the LVs was stained 
by Masson's trichrome technique allowing for quantification 
of infarct size in MI model and total fibrosis.34 The amount 
of apoptotic cells was determined by terminal deoxynucleoti-
dyl transferase-mediated dUTP nick end labelling (TUNEL) 
method, according to the manufacturer's protocol (ApopTag 
Red in situ apoptosis detection kit, Chemicon International, 
CA, USA).30 Primary antibodies were used to label prolif-
erating cells (anti-Ki-67, M7248, Millipore, Darmstadt, 
Germany), angiogenesis (von Willebrand factor, vWF, 
AB7356, Abcam, Cambridge, UK) and c-kit positive cells 
(anti-c-kit, sc-168, Santa Cruz, CA, USA). The immunohis-
tochemical detections were visualized with AT2 Aperio scan-
ner (Leica Biosystems, CA, USA) at the Northern Finland 
Borealis Biobank (Oulu University Hospital, Finland). For 
double staining, epitope retrieval was done by heating the 
sections in a microwave oven in tri-sodium citrate solution 
(pH 6.0) for 15 minutes and allowed to cool down at room 
temperature for 30 minutes. Sections were blocked in 0.2% 
horse serum, 2% bovine serum albumin and 0.2% Triton in 
PBS for 30 minutes and incubated with primary antibodies 
in a humidified chamber at RT for 30  minutes and at 4°C 
overnight.34 The sections were co-incubated with primary 
antibodies for GATA4 (sc-9053, Santa Cruz), P4H (prolyl-
4-hydroxylase, MAB2073, Millipore), αAct (sarcomeric 
α-actinin, A7811, Sigma-Aldrich, MO, USA) or Acta2 
(smooth muscle actin, AB5694, Abcam). For visualization 
anti-rabbit CY3 (611-104-122, Rockland, PA, USA), bi-
otinylated antimouse (BA-2001, Vector laboratories, CA, 
USA) and DAPI, for nuclei (D9542, Sigma-Aldrich), were 
used. Images were generated with the digital slide scanner 
3DHISTECH Pannoramic 250 FLASH II at the Genome 
Biology Unit (Research Programs Unit, Faculty of Medicine, 
University of Helsinki, Biocenter Finland, Finland) and the 
Institute of Biotechnology (University of Helsinki, Finland).
2.5 | Primary neonatal rat ventricular 
fibroblasts culture
Neonatal rat ventricular fibroblasts (NRVFs) were isolated from 
2- to 4-day-old Sprague Dawley rats using the collagenase dis-
sociation method, as described previously.22 The animals were 
killed by decapitation, the hearts were excised, and the ventri-
cle chambers were separated and processed towards NRVFs 
isolation. Myocyte and non-myocyte cells were separated by 
differential attachment preplating, where the attached frac-
tion is enriched with fibroblasts. NRVFs were passaged once 
and seeded for the experiment into multi-well plates at density 
0.75-1 × 105 cell/cm2. The cells were maintained 18-24 hour 
in Dulbecco's modified Eagle's medium (DMEM)/F-12 sup-
plemented with 10% foetal bovine serum and 100 IU/mL pen-
icillin-streptomycin. The next day, NRVFs were transfected 
with Ad1-GATA4 or Ad5-GATA4-S105A and Ad5-nls-LacZ 
in serum-free conditions. Briefly, the cells were washed and 
switched to culture serum-free media (CSFM), containing 
DMEM/F-12 supplemented with 2.5 mg/mL bovine serum al-
bumin, 1 μM insulin, 2.8 mM sodium pyruvate, 5.64 μg/mL 
transferrin, 1  nM T3 and 100  IU/mL penicillin-streptomycin 
(all the cell culture medium components were purchased from 
Sigma-Aldrich). Adenoviruses were added to the cells at the 
appropriate concentrations to achieve 2 and 4 multiplicity of 
infection units (MOI) and incubated at 37°C and 5% CO2. The 
NRVFs were maintained in CSFM, which was replaced every 
24 hour. After 48 hour, the cells were washed twice with ice-
cold PBS and quickly frozen at −70°C.
2.6 | Real-time quantitative PCR
The basal transversal mid-section of the LV was dissected 
and snap frozen in liquid nitrogen. Next, the tissues were 
processed for total RNA isolation by the guanidine thiocy-
anate-CsCl method.33 The cDNA was synthesized using 
the RNA isolated from the tissue homogenates as template, 
using Transcriptor First-Strand cDNA Synthesis Kit (Roche 
Diagnostics, Mannheim, Germany) according to the manu-
facturer's instructions. Isolation of RNA from NRVFs was 
achieved by using the EZNA® Total RNA Kit I (Omega 
Bio-Tek, Norcross, GA, USA) according to the manufac-
turer's instructions. Real-time quantitative polymerase chain 
reaction (RT-qPCR) with FastStart Universal Probe Master 
(Roche, Basel, Switzerland) was used for RNA expression 
analysis on an ABI 7300 sequence detection system (Applied 
Biosystems, Life Technologies, MA, USA), as previously 
described.35 The primers and fluorogenic probes used for RT-
qPCR were all purchased for Sigma-Aldrich and are listed in 
Table S1. The results were normalized to GAPDH mRNA 
quantified from the same samples and then normalized to the 
LacZ control group.
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2.7 | Western blotting
The basal transversal mid-section of the LV was dissected 
and snap frozen in liquid nitrogen. Next, the tissues were 
processed for total and nuclear protein extractions, as previ-
ously described.30,33 Equal amounts of protein were loaded 
onto 10% SDS-PAGE and transferred to nitrocellulose mem-
branes. Primary antibodies against total GATA4 (sc-9053, 
Santa Cruz), phosphorylated GATA4 at S105 (44-948, 
Invitrogen, CA, USA) and Lamin B (sc-6216, Santa Cruz) 
were used according to the manufacturers’ instructions and 
detected with fluorescent secondary antibodies: anti-rabbit 
and antimouse IgG Alexa Fluor 680 (A21076 and A21058, 
Invitrogen), anti-rabbit IgG IRDye 800 (926-32211, LI-COR 
Biosciences, Lincoln, NE, USA) and anti-goat IRDye 700 
(605-730-125, Rockland). Protein levels were visualized 
with Odyssey Fc imaging system (LI-COR Biosciences).
2.8 | Statistics
The values are represented as mean and standard deviation. 
Student's t test was used to compare GATA4 or GATA4-
S105A groups to its dose-matched LacZ control. The differ-
ent LacZ control groups are not comparable to each other due 
to the different doses. Welch's corrected t test was used when 
the variances were unequal between the groups. If the values 
were not normally distributed, the data were represented as 
median and interquartile range, and Mann-Whitney U test 
was used to comparisons between two groups. For multi-
ple comparisons, statistical significance was evaluated by 
one-way ANOVA followed by a least significant difference 
(LSD) post hoc test. Alternatively, Kruskal-Wallis test was 
used for multiple comparisons when the variances were un-
equal between groups. Data were analysed using GraphPad 
Prism v.7.02 (GraphPad Software Inc, CA, USA). A P-
value < .05 was accepted as statistically significant.
3 |  RESULTS
3.1 | GATA4 is localized into cardiac 
myocytes, fibroblasts and myofibroblasts by 
intramyocardial adenoviral gene delivery in 
vivo
To study the effect of GATA4 overexpression on AngII-
induced adaptive stress response, we used a gain-of-func-
tion approach by which adenoviral constructs were locally 
injected into the LV. To confirm GATA4 overexpres-
sion in LVs, we measured the mRNA levels by RT-qPCR. 
As shown in Figure 2A, GATA4 mRNA levels were sig-
nificantly increased at one week (4.7-fold, P  =  .017) and 
remained elevated at two weeks. The protein levels of both 
total GATA4 and GATA4 phosphorylated at S105 were also 
increased at one week (Figure 2B). The efficiency and locali-
zation of GATA4 gene delivery was further determined by 
immunofluorescence double staining with αAct marker for 
CMs, whereas P4H and Acta2 were used to detect fibroblasts 
and activated fibroblasts, respectively. GATA4 co-localized 
mostly with αAct (Figure 2C) but was also detected in cells 
expressing P4H (Figure 2D) and Acta2 (Figure 2E): approxi-
mately 87% of GATA4-positive cells were myocytes, 12% 
fibroblasts and 10% activated fibroblasts.
3.2 | GATA4 modulates the AngII-induced 
fibrotic response
To evaluate the potential role of GATA4 in modulating AngII-
induced fibrotic response, we quantified Masson's trichrome 
staining of LV transversal slices. The degree of fibrosis ana-
lysed by Masson's trichrome staining was not significantly al-
tered (Figure 3A, B). Next, the effect of GATA4 overexpression 
on AngII-induced activation of fibrotic genes was measured by 
RT-qPCR (Figure 3C-K). At two weeks, we detected signifi-
cant changes in the expression of pro-fibrotic genes: fibronectin 
(FN) 1, collagens (Col) 1a1 and 3a1, TGFβ1, metalloproteinase 
(MMP) 2 and MMP9 expressions were all significantly reduced 
more than 50% (Figure 3C-H). Furthermore, the expression of 
tissue inhibitor metalloproteinase type 1 (TIMP1) was strongly 
repressed (80%, P = .021; Figure 3I). Also, fibroblast growth 
factor type 2 (FGF2), a promoter of cardiac hypertrophy and 
fibrosis through MAPK signalling,36 was down-regulated 
(Figure 3J). The phenylephrine-induced complex-1 (PEX1) 
transcription factor has been demonstrated to collaborate with 
GATA4 to promote the hypertrophic response in CMs 37,38 
and to possess pro-fibrotic actions through promoting MMP9 
expression.34 Interestingly, PEX1 mRNA levels were signifi-
cantly down-regulated (39.7%, P  <  .000; Figure 3K) in left 
ventricles of AngII-induced hypertensive rats overexpressing 
GATA4 when compared to the LacZ group.
3.3 | GATA4 overexpression and AngII-
induced cardiac hypertrophic response
There is evidence demonstrating the role for GATA4 tran-
scriptional control in CM hypertrophic growth.18,20,22,39-42 
Therefore, we measured the expression of genes associated 
with cardiac hypertrophy (Figure 4A-I). In response to AngII, 
atrial natriuretic peptide (ANP) mRNA levels were signifi-
cantly decreased (53.8%, P =  .024, Figure 4A) by intramy-
ocardial adenoviral GATA4 gene transfer. In addition, the 
α-myosin heavy chain (MHC) to foetal isoform β-MHC ratio 
was significantly increased (1.8-fold, P = .044) at two weeks 
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(Figure 4D-F) by GATA4 overexpression, whereas cardiac 
α-actin (Actc1) adult isoform expression was up-regulated 
and cardiac-to-skeletal α-actin ratio (Actc1/Acta1) was signifi-
cantly higher (1.6-fold, P = .015) at one week (Figure 4G-I), 
thus showing that overexpression of GATA4 prevented the 
AngII-induced adult-to-foetal isoform switch of these proteins.
3.4 | GATA4 overexpression decreases 
apoptosis and prevents cell proliferation in the 
AngII-induced hypertension
GATA4 is also a prosurvival factor33 and has been reported 
to regulate cell survival through promoting the expression 
of anti-apoptotic factor Bcl2.27,43 Therefore, we examined 
histological sections from GATA4 overexpressed LVs in 
AngII-induced hypertension for apoptotic cells using the 
terminal deoxynucleotidyl transferase-mediated dUTP nick 
end labelling (TUNEL) method or proliferating cells with 
Ki-67 cell cycle marker. A significantly lower number of 
TUNEL-positive cells (Figure 5A, B) and Ki-67 positive 
cells (Figure 5C, D) were observed in GATA4 overexpress-
ing hearts compared to the LacZ control group at one week 
of starting AngII infusion. Although we did not address in 
detail the cell specificity, based on the cellular morphol-
ogy observed in the histological stainings, the apoptotic and 
proliferating cells were mostly non-myocytes, as reported 
also previously.33 The cardioprotective role of GATA4 in 
F I G U R E  2  GATA4 overexpression 
by intramyocardial adenoviral gene 
delivery into the LV in AngII-induced 
hypertension in rats. (A) RT-qPCR was used 
to quantify the mRNA levels of GATA4 
at 1 and 2 wks. The bars represent average 
values + SD (n = 6-8/group). * P ≤ .05, ** 
P ≤ .01. (B) Protein levels were examined 
by immunoblotting for GATA4, GATA4 
phosphorylation at S105 (GATA4-pS105) 
and Lamin B. Figure shows a representative 
Western blot at 2 wks (full blot images in 
Fig. S1). (C-E) Immunofluorescent study of 
GATA4 (red) for cellular localization using 
specific cell markers for myocytes (αAct, 
C), fibroblasts (P4H, D) and myofibroblasts 
(Acta2, E). Representative LV histological 
sections are shown, white arrows indicate 
co-localization with the specific cell 
markers (LacZ control group representative 
images are shown in Fig. S2). The scale bars 
represent 25 µm
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adult rat heart after MI has been associated with angiogen-
esis,33 but in AngII-induced hypertension we did not detect 
any changes in the number of capillaries in GATA4 overex-
pressed LVs (Figure 5F).
3.5 | Overexpression of GATA4-S105A was 
deleterious for cardiac structure and function
Echocardiography assessment showed that adenovirus-
mediated overexpression of GATA4 caused no change in 
the LV dimensions or function when compared to the LacZ 
control group in AngII-induced hypertension within two 
weeks (Figure 6 and Table S2). In contrast, overexpressing 
GATA4 with a mutation at serine 105 to alanine (GATA4-
S105A) produced LV dysfunction, this being strongest at 
one week after the interventions (Figure 6 and Table S2). 
The dimension of the LV chamber was significantly en-
larged in GATA4-S105A overexpressing hearts compared 
to the LacZ group, as demonstrated by augmented LV in-
ternal diameter (Figure 6A) and thinner LV posterior wall 
in diastole (Figure 6B) and systole. Furthermore, the en-
docardial fractional area change (FAC), which provides an 
estimate of the area change within the LV between dias-
tole and systole, was significantly decreased (Figure 6D). 
These structural changes were translated into impairment 
of the LV function, as shown by an increase of the LV 
volume (Figure 6E), and significantly worsened LV ejec-
tion fraction (EF, −25%, P  =  .009) and fractional short-
ening (FS, −30%, P  =  .009; Figure 6F, G). At 2  weeks, 
similar alterations in structural and functional parameters 
were still evident, even though the differences were more 
moderate (Table S2). Of note, the adenoviral dose required 
for GATA4 and GATA4-S105A overexpressions (1 × 109 
pfu and 2 × 109 pfu, respectively) to achieve the matched-
dose LacZ controls resulted in differences in baseline lev-
els of echocardiographic parameters between LacZ control 
groups.
F I G U R E  3  The effect of GATA4 
overexpression on AngII-induced fibrosis. 
(A and B) Masson's trichrome staining 
was used to quantify the percentage of 
fibrosis in LVs at 2 wks (A, n = 7-8/group). 
The results are average values ± SD. 
Representative images (B) are shown where 
the collagenous fibres are stained blue. 
The scale bars represent 75 µm. (C-K) The 
mRNA levels of fibrosis-associated genes 
FN1, Col1a1, Col3a1, TGFβ, MMP2, 
MMP9, TIMP1, FGF2 and PEX1 at 1 and 
2 wks were quantified by RT-qPCR. The 
values were normalized to GAPDH and are 
expressed as relative to LacZ control groups 
(n = 6-8/group). The results are represented 
as average + SD or median + interquartile 
range [FN1, 2 wks]. * P ≤ .05, ** P ≤ .01, 
*** P ≤ .005
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3.6 | Effects of overexpression of GATA4-
S105A on cardiac gene expression in AngII-
induced hypertension
Since the functional effects of GATA4-S105A overexpres-
sion in response to AngII were deleterious, we proceeded 
to evaluate the possible underlying cellular and genetic 
mechanisms. When mutated GATA4-S105A adenoviral 
construct was locally injected into the heart, GATA4 mRNA 
levels were significantly augmented at one week (5.5-fold, 
P < .001) and two weeks (2.0-fold, P = .015; Figure 7A). 
Moreover, as anticipated, the amount of GATA4 phospho-
rylated at S105 did not increase after intramyocardial ad-
enoviral delivery (Figure 7B). Quantification of TUNEL, 
Ki-67 or Masson's trichrome stainings of LVs overexpress-
ing GATA4-S105A revealed no differences when compared 
to the LacZ control group (Figure 7C-F). Furthermore, when 
the changes in gene expression were assessed by RT-qPCR 
analysis, GATA4-S105A overexpression provoked a differ-
ent fibrotic gene expression pattern (Figure 8A-I) from that 
induced with GATA4 overexpression (Figure 3C-K). FN1 
mRNA expression was significantly up-regulated (2.3-fold, 
P = .006) at one week of AngII infusion (Figure 8A), and 
slightly decreased mRNA levels were observed for Col1a1, 
Col3a1, TGFβ1, MMP2, MMP9 and PEX1 but these changes 
were not statistically significant (Figure 8B-G). TIMP1 gene 
expression was significantly down-regulated at one and two 
weeks (66%, P = .022; 55%, P = .015, respectively; Figure 
8H), and FGF2 mRNA levels were also down-regulated at 
one week (Figure 8I), similarly to GATA4 overexpressing 
animals (Figure 3I, J). Altogether, these results suggest that 
the expression of pro-fibrotic genes depends on GATA4 
S105 phosphorylation. The genes involved in the cardiac 
hypertrophic response, such as ANP, BNP and FGF1, were 
significantly up-regulated at one week (Figure 8J-L) as well 
as the mRNA levels of both adult and foetal isoforms of 
contractile proteins (Figure 8M-R).
3.7 | Differential effects of GATA4 and 
GATA4-S105A overexpression on isolated 
cardiac fibroblast
Since in vivo findings indicated that GATA4 S105 phospho-
rylation plays a role particularly in the modulation of the fi-
brotic response to Ang II, we next used isolated NRVFs to 
conduct gain-of-function studies by transfecting cells with 
wild-type GATA4 and S105A mutated GATA4 adenoviral 
constructs as well as LacZ control. In these experiments, 
two different multiplicity infectious units (MOI) were used 
(2 MOI and 4 MOI). All NRVFs experiments were cat-
egorized into three groups based on the level of GATA4 
overexpression achieved with GATA4 wild-type construct. 
Transfections for 48 hours with the wild-type GATA4 ad-
enovirus construct resulted in 6-fold and 16-fold increase 
of GATA4 mRNA levels at 2 MOI and 73-fold increase at 
4 MOI (P < .001 in all; Figure 9A), the different expres-
sion levels with 2 MOI likely being related to the variabil-
ity of cell density between experiments. Overexpression 
with mutated GATA4-S105A construct increased GATA4 
mRNA significantly at 4 MOI (39-fold, P <  .001; Figure 
9A). Overexpression of GATA4 adenovirus for 48  hours 
F I G U R E  4  Analysis of hypertrophy-
associated genes in LVs at 1 and 2 wks after 
intramyocardial adenoviral GATA4 gene 
delivery. (A-I) ANP, BNP, FGF1, αMHC, 
βMHC, Actc1 and Acta1 mRNA levels 
were quantified by RT-qPCR. The mRNA 
values were normalized to GAPDH and are 
expressed as relative to LacZ control groups 
(n = 6-8/group). The results are represented 
as average + SD or median + interquartile 
range [Actc1/Acta1 ratio, 1 wk]. *P ≤ .05, 
**P ≤ .01
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resulted in small increases in FN1, Col1a1 and MMP2 
mRNA levels (Figure 9B, C and F), while the mRNA 
levels of MMP9 decreased significantly (Figure 9G). No 
changes in mRNA levels of Col3a1, TGFβ1, TIMP, FGF2 
and PEX1 were noted with wild-type GATA4 overexpres-
sion (Figure 9D, E, H-J). Interestingly, GATA4-S105A 
overexpression provoked significantly lower mRNA lev-
els of FN1, Col1a1, Col3a1, MMP2, TIMP1, FGF2 and 
PEX1 when compared to the wild-type GATA4 adenovi-
rus construct or the LacZ control group (Figure 9B-D, F 
and H-J). Taken together, these results show that the pro-
fibrotic gene expression also in isolated cardiac fibroblasts 
depends on GATA4 S105 phosphorylation.
3.8 | GATA4-S105A overexpression by 
intramyocardial adenoviral gene delivery failed 
to rescue the infarcted heart
Previously, we have reported that GATA4 adenoviral gene 
delivery restores cardiac function, as shown by improved 
LV EF and FS, in the LAD ligation experimental model 
of MI through reduced infarct size, increased number 
of capillaries and stem-like cells, and reduced apopto-
sis.33 Therefore, in separate series of experiments, we 
also explored the effects of GATA4-S105A overexpres-
sion on cardiac function and structure after MI in rats. 
Overexpression of mutated GATA4-S105A at three days, 
one week and two weeks after local LV gene transfer in the 
sham-operated animals resulted in significantly elevated 
GATA4 mRNA levels throughout the follow-up period 
(at three days, 14.8-fold, P =  .005; Figure 10A). In LVs 
of infarcted hearts, GATA4 mRNA levels were elevated 
at three days compared to the LacZ controls (11.8-fold, 
P =  .074), while no significant changes were seen at one 
and two weeks (Figure 10B). Echocardiography evaluation 
revealed no effects of GATA4-S105A overexpression on 
cardiac structure and function neither in sham nor in in-
farcted hearts (Figure 10B-E and Table S3). Accordingly, 
immunohistological examinations showed no changes in 
GATA4-S105A-treated hearts regarding the number of 
capillaries, and c-kit-, Ki-67-, TUNEL-positive cells or 
F I G U R E  5  Effect of GATA4 
overexpression on apoptosis, cell 
proliferation, stem cell-like cells and 
angiogenesis in LVs of 2 wks AngII-induced 
hypertension. Immunohistochemical 
staining for TUNEL-positive cells was 
used to determine the number of apoptotic 
cells in LVs (A). Representative images are 
shown (B). Immunohistochemical staining 
against Ki-67 was used to determine 
the effect on cellular proliferation (C), 
representative images are shown (D). (E) 
c-kit antibody was used to quantify stem 
cell-like cells. (F) Histological sections were 
stained with vWF to determine the number 
of capillaries. The whole LV was scanned, 
and positive cells were counted from high 
power fields (40×) selecting 6-8 hotspots. 
The scale bars represent 100 µm. The results 
are represented as average + SD (n = 7-8/
group). * P ≤ .05
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Masson's staining quantification of fibrosis (Figure 10F-I). 
Importantly, the infarct size was not significantly different 
in infarcted hearts overexpressing GATA4-S105A when 
compared to the LacZ control group (Figure 10J).
4 |  DISCUSSION
In this study, we showed that GATA4 gain-of-function in 
AngII-induced hypertension in rats modulates the left ven-
tricular remodelling by altering the expression of pro-fibrotic 
and hypertrophic genes as well as by decreasing apoptosis and 
cell proliferation. Myocardial GATA4 overexpression alone 
did not have any effects on cardiac function or structure, but 
loss of GATA4 S105 phosphorylation in AngII-induced hy-
pertension caused LV dilatation and thinning of the walls, 
resulting in eccentric LV hypertrophy and decompensated 
heart function. Furthermore, GATA4-S105A overexpression 
had minor or no effect on the pro-fibrotic gene expression, 
apoptosis or cell proliferation in LVs in response to AngII-
induced pressure overload. Interestingly, GATA4 overex-
pression had also almost no effect on expression of fibrotic 
genes in isolated cardiac fibroblasts, but loss of S105 phos-
phorylation site decreased the expression of ECM genes es-
sential for left ventricular remodelling. Finally, we observed 
that intramyocardial adenovirus-mediated gene transfer of 
GATA4-S105A in rats did not reproduce the cardioprotective 
effects of GATA4 after MI, as reported earlier.33 Collectively, 
our findings highlight the importance of phosphorylation site 
S105 for GATA4 transcriptional activity and cardioprotec-
tive effects in experimental models of hypertension and MI 
in the adult rat heart (Figure 11).
The direct local injection of adenovirus constructs into 
the LV used in this study has previously been documented 
F I G U R E  6  Effect of GATA4 and 
GATA4-S105A overexpression on cardiac 
function and structure in AngII-induced 
hypertension in rats. (A-G) Structural and 
functional parameters were analysed at 1 wk 
by echocardiography in rats overexpressing 
GATA4 or GATA4-S105A and their 
dose-matched LacZ control groups. Due 
to different virus dose, the control LacZ 
groups are not comparable to each other. 
The results are represented as average + SD 
or median + interquartile range [LVPW, 
GATA4-S105 and LacZ control] (n = 7-10/
group). LVID = left ventricular internal 
diameter; LVPW = left ventricular posterior 
wall thickness; IVS = interventricular 
septum; FAC = fractional area change; LV 
vol. = left ventricular volume; LVEF = left 
ventricular ejection fraction; LVFS = left 
ventricular fractional shortening. * P ≤ .05, 
** P ≤ .01, *** P ≤ .005
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as an efficient cardiac-specific approach of gene deliv-
ery.30,32-35,44-46 This protocol targets elevated expression of 
the transgene into the LV without affecting other organs and 
thereby provides a precise approach to study the short-term 
effects of the selected transgene, thereby mimicking pharma-
cotherapy approaches. Delivery of adenoviral constructs by 
LV intramyocardial injection, however, also limits the amount 
of the exogenous gene expression to a portion of cells sur-
rounding the injections area in the myocardium.30,32-35,44-46 
Moreover, since we analysed gene expression of total LV 
RNA, the effects observed by overexpressing GATA4 and 
S105 mutated GATA4 reflect changes both in infected and 
non-infected cells as well as direct and indirect effects of 
gene delivery in multiple cardiac cell types. Consequently, 
since GATA4 was mostly overexpressed in CMs in the adult 
heart, the changes in cardiac gene expression may also be 
due to the paracrine effect of GATA4 overexpression in 
cardiomyocytes.
Previous studies have demonstrated increased cardiac 
fibrosis consequent to loss of GATA4, along with ele-
vated apoptosis and compromised hypertrophic response 
to transverse aortic constriction (TAC)-induced pressure 
overload.25,39 Furthermore, van Berlo and colleagues 47 re-
ported LV dilatation in S105 mutant mice after TAC, along 
with increased fibrosis. In the present study, the local and 
short-term effects of GATA4 or GATA4-S105A overex-
pression on the LVs were studied during the initial response 
to AngII-induced hypertension. GATA4 overexpression in 
LVs of normal adult rats blunted AngII-induced fibrotic 
gene response through down-regulation of ECM struc-
tural and matricellular proteins such as Col1a1, Col3a1, 
FN1 and TGFβ1, as well as metalloproteases MMP2 and 
MMP9, and their inhibitor TIMP1. Moreover, loss of 
S105 phosphorylation mostly prevented GATA4-mediated 
down-regulation of pro-fibrotic genes. However, the extent 
of fibrosis was not altered by histological analysis. This 
might be related to the progressive increase in interstitial 
fibrosis typically observed in pressure overload type of car-
diac stress,48 and thus, changes in its composition might be 
observable later than within two weeks. When TAC was 
performed on S105 mutant mice, the expression of ECM 
associated genes was hindered although fibrosis percentage 
F I G U R E  7  Effect of GATA4-S105A 
overexpression on fibrosis, apoptosis and 
cell proliferation in LVs of 1 wk AngII-
induced hypertension. Overexpression 
of GATA4 by local adenoviral gene 
transfer at 1 and 2 wks was confirmed by 
RT-qPCR (A) and Western blotting (B). 
Representative blot of 1 wk samples is 
shown (full blot images in Fig. S3). Fibrosis 
was quantified by Masson's trichrome 
staining (C), representative images from LV 
histological sections are shown (D). The 
scale bar represents 75 µm. (E) The number 
of apoptotic cells was quantified from 
TUNEL staining. (F) Immunohistochemical 
staining against Ki-67 was used to 
determine number of proliferating cells 
in LV histological sections. The results 
are represented as average ± SD (n = 6-7/
group). * P ≤ .05, *** P ≤ .005
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was increased.47 When compared to TAC, AngII infusion 
more specifically activates signalling pathways that bring 
GATA4 activation through S105 phosphorylation.17,19,23,24 
AngII activates distinct MAPK signalling pathways in 
CMs and CFs by interaction with AT1-R, and activation 
of ERK1/2 and p38 MAPKs in CMs have been indicated 
as upstream regulators of GATA4 DNA binding ability 
and transcriptional potency through phosphorylation of 
S105.17,19,21 In addition, GATA4-S105A knock-in mice can 
no longer phosphorylate S105 and GATA4 transcriptional 
activity dependent on S105 is completely abolished from 
embryonic development to adulthood,47 whereas in our 
present experiments, the GATA4-S105 phosphorylation 
is only partly inhibited in GATA4-S105A overexpressed 
hearts as baseline S105 phosphorylation of endogenous 
GATA4 can still exist. Therefore, loss of baseline effects of 
GATA4 transcription activity in GATA4-S105A knock-in 
mice might have exacerbated the impaired pressure over-
load response. However, it is noteworthy that in our in vivo 
experimental animal model of hypertension, it is not possi-
ble to distinguish between the direct AngII-induced and the 
pressure load-induced responses.
The studies conducted in isolated cardiac fibroblasts 
showed that overexpression of GATA4 had only a modest 
effect on the expression of pro-fibrotic genes. In contrast, 
GATA4-S105A overexpression in NRVFs provoked a strong 
F I G U R E  8  Analysis of gene 
expression in LVs at 1 and 2 wks after 
GATA4-S105A gene delivery in AngII-
induced hypertension. The mRNA levels 
of fibrosis-associated genes (A-I) and 
hypertrophic-associated genes (J–R) were 
quantified by RT-qPCR. The expression 
values were normalized to GAPDH and are 
expressed as relative to LacZ control groups 
(n = 6-8/group). The results are represented 
as average + SD or median + interquartile 
range [Col1a1, MMP9, FGF2, βMHC, 
Acta1 and Actc1/Acta1 ratio, 1 wk].  
* P ≤ .05, ** P ≤ .01, *** P ≤ .005
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down-regulation of FN1, Col1a1, Col3a1, MMP2, MMP9, 
TIMP1, FGF2 and PEX1 gene expressions. These results 
clearly show the differential effects of GATA4 on fibrotic gene 
expression due to GATA4 loss of S105 phosphorylation, sug-
gesting a regulatory role for GATA4 in ECM gene expression 
in cardiac fibroblasts. However, it must be noted that isolated 
cell experiments cannot fully reproduce the intact myocardium 
environment, where cell-to-cell and the ECM cells communi-
cations are present. Nevertheless, the importance of phosphor-
ylation at S105 for GATA4 modulation of pro-fibrotic gene 
expression was observed both in vivo in the adult rat heart and 
in the isolated neonatal rat cardiac fibroblasts.
The most prominent actions of GATA4 during LV remod-
elling involve modulation of CM growth. GATA4 directly 
activates the expression of hypertrophic gene response such 
as ANP, BNP, β-MHC, α-MHC and Acta1.24,41,49,50 The hy-
pertrophic programme drives CM growth predominantly in 
width, resulting in LV concentric hypertrophy. In our present 
study, GATA4 did not promote the hypertrophic gene pro-
gramme in the AngII-induced hypertension. It is likely that 
existing high levels of GATA4 activity in response to AngII 
infusion24 might be accountable for the negligible effect of 
further increasing GATA4. Intriguingly, GATA4-S105A 
overexpression steered AngII-induced concentric hypertro-
phy towards deleterious eccentric LV hypertrophy, which led 
to impaired cardiac function. LV dilatation has been linked 
to elevated MMPs in the late stages of post-MI and pressure 
overload remodelling.7 Likewise, increased MMP9 activity 
has been associated to the transitional phase from compensa-
tory response to heart failure in hypertensive patients.51 Since 
TIMP1 expression was strongly suppressed both in isolated 
CFs and in AngII-induced hypertension in vivo by GATA4-
S105A overexpression, it may have contributed to eccentric 
hypertrophy and LV dilatation, and also suggest that GATA4 
by lowering the MMP9-to-TIMP1 ratio may attenuate the 
fibrotic process. Furthermore, we speculate that the struc-
tural changes occurring in CMs during eccentric hypertro-
phy might be accountable for the strong induction of FN1 
expression observed in GATA4-S105A hypertensive hearts. 
Fibronectin is anchored to the cell surface of CMs, and it 
binds to integrins and triggers signalling pathways involved 
in migration, proliferation, survival, cell growth, and actin 
cytoskeleton reorganization.7
Our results indicate that GATA4 inhibits AngII-induced 
apoptosis and diminishes the number of proliferating cells. 
These findings agree with the previous studies on the an-
ti-apoptotic actions of GATA4 during myocardial remod-
elling. GATA4 overexpression has been shown to reduce 
post-MI apoptosis,25 whereas CM-specific loss of GATA4 
led to increased apoptosis and cell loss in TAC-induced 
F I G U R E  9  Assessment of fibrosis-
associated genes expressions in NRVFs after 
GATA4 and GATA4-S105A adenovirus-
mediated overexpression for 48 hrs. 
The experiments are grouped into 3 sets 
according to the adenovirus concentration: 
2 MOI (+; ++) and 4 MOI (+++). GATA4 
overexpression (A) and the mRNA levels 
of fibrotic genes FN1, Col1a1, Col3a1, 
TGFβ1, MMP2, MMP9, TIMP1, FGF2 and 
PEX1 (B-J) were quantified by RT-qPCR. 
The expression values were normalized to 
GAPDH and are expressed as relative to 
LacZ control groups (n = 3-4/group). The 
results are represented as average + SD.  
* P ≤ .05, ** P ≤ .01, *** P ≤ .005 vs 
LacZ. # P ≤ .05, ## P ≤ .01, ### P ≤ .005 
vs GATA4
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pressure overload.25,39 At tissue level, these processes are 
tightly linked; therefore, reduced cell death might be ac-
countable for diminished cell proliferation. Previously, we 
have reported cardioprotective actions for GATA4 by using 
adenoviral gene delivery in experimental rat model of 
MI.33 Interestingly, in the present study, overexpression of 
mutant GATA4-S105A had no effects on cardiac function 
and structure post-infarction, whereas it was deleterious 
in Ang II-induced pressure overload, precipitating the de-
velopment of eccentric hypertrophy and dysfunctional LV 
dilatation. It is likely that these different actions of GATA4 
in specific pathological contexts might be explained by the 
aetiology of the stimuli, hypertension vs MI, and their dis-
tinctive remodelling and fibrotic processes. The pressure 
overload response is characterized by myocardial hyper-
trophy and diffuse reactive fibrosis triggered by neurohu-
moural factors and increased haemodynamic load whereas 
post-MI remodelling is driven by the ischaemic injury, me-
chanical stress and cell damage.9,52,53
Besides MAPK-mediated phosphorylation of S105, other 
post-translational modifications (PTMs) and protein-protein 
interactions are also known to regulate GATA4 activity.23,54 
F I G U R E  1 0  The effects of GATA4-S105A overexpression by intramyocardial gene delivery after myocardial infarction in rats. (A) 
RT-qPCR quantification of GATA4 mRNA levels in LVs of sham-operated and MI animals at 3 d, 1 and 2 wks. The values were normalized 
to GAPDH and are expressed as relative to sham LacZ control groups at each time point. The bars represent average values + SD (n = 5-8/
group). * P ≤ .05, ** P ≤ .01, *** P ≤ .005 Sham GATA4-S105A compared to LacZ group and # P ≤ .05 MI GATA4-S105A compared to LacZ. 
(B-E) Echocardiographic measurements were performed at 2 wks after infarction and gene transfer. LVEF = left ventricular ejection fraction; 
LVFS = left ventricular fractional shortening; LVPW = left ventricular posterior wall thickness; LVID = left ventricular internal diameter. (F-I) 
Immunohistochemistry studies for apoptosis (TUNEL, F), c-kit-positive cells (G), fibrosis (Masson's trichrome, H) and angiogenesis (vWF, I) 
from LV histological sections at 2 wks after MI and injection of the adenoviral constructs. (J) The infarct area was measured from 3 d and 2 wks 
histological LV sections stained with Masson's trichrome. The results are represented as average ± SD (n = 5-8/group)
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Activation of GATA4 by AngII is partly mediated by pro-
tein kinase C (PKC)-mediated phosphorylation at S419/420 
of GATA4 by glycogen synthase kinase 3-beta (GSK3β) 
signals for nuclear export and, therefore, decreases GATA4 
transcriptional activity in cardiomyocytes.55 In contrast, 
K366 SUMOylation promotes nuclear localization and 
enhances GATA4 activity.56 The phosphorylation of S261 
by ERK1/2, ribosomal s6 kinase (RSK) or protein kinase 
A (PKA) promotes the association of GATA4 with p300, 
while K299 methylation by polycomb repressive complex 
2 (PRC2) attenuates it. Histone acetyltransferase p300, in 
turn, induces CM hypertrophy through acetylation of 4 ly-
sine residues in the C-terminus of GATA4.57 Regulation 
of GATA4-dependent gene transcription in cardiac stress 
response is intricately modulated by co-ordinated PTMs 
and physically interacting partners. Further, GATA4 and 
GATA6 are co-expressed in CM and have been shown to 
act in synergy to promote the expression of hypertrophic 
genes in CM, but also to be independently sufficient.50,58 
They also distinctly regulate sets of genes required for the 
adaptive response to pressure overload, such as angiogene-
sis.59 Thus far, the possibility that GATA6 and other PTMs 
could be used as strategies to, at least partly, compensate 
for the lack of S105 phosphorylation-associated GATA4 
activity cannot be excluded. Therefore, further studies are 
needed to address the precise molecular actions of GATA4 
in the adult heart.
5 |  CONCLUSION
In summary, we show by using local adenoviral gene 
transfers that the cardioprotective effects of GATA4 dur-
ing AngII-induced hypertension require activation through 
GATA4 phosphorylation at S105. Furthermore, we ob-
served that GATA4 actions are tightly associated with 
down-regulation of pro-fibrotic genes in adaptive response 
to AngII. In addition, the GATA4 actions on cardiac fi-
broblasts are dependent on phosphorylation site S105. 
Taking together, these findings underscore the importance 
F I G U R E  1 1  Schematic illustration 
of GATA4 actions induced upon 
cardiac stress. Stress signals activate 
intracellular signalling cascades that 
lead to activation of GATA4 through 
post-translational modifications, such as 
phosphorylation at serine 105. GATA4 
then contributes to the adaptive response 
of the myocardium through modulation 
of genes involved in angiogenesis, 
hypertrophic growth, cell survival and 
the fibrotic process. ACTA1 = Skeletal 
muscle actin, alpha 1; AngII = angiotensin 
II; ANP = atrial natriuretic peptide; 
BCL = B-cell lymphoma; BNP = B-type 
natriuretic peptide; Col = collagen; 
ET-1 = endothelin-1; JAK/STAT = janus 
kinase/signal transducer and activator of 
transcription; MAPKs = mitogen-activated 
protein kinases; MHC = myosin heavy 
chain; MMP = metalloproteinase;  
NFAT = nuclear factor of activated T cells;  
PE = phenylephrine; PKC = protein 
kinase C; TIMP = tissue inhibitor 
metalloproteinase; Snai1 = Snail 
family transcriptional repressor 1; 
VEGF = vascular endothelial growth factor
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of phosphorylation site S105 for GATA4 transcriptional 
activity and cardioprotective effects in AngII-induced ex-
perimental model of hypertension. Although the role of 
GATA4 in fibrosis might have been previously considered 
subsequent to the effects on cardiomyocyte hypertrophy 
and survival, recent findings support a more direct role of 
GATA4 in modulating fibrotic gene expressions.28,33 For 
example, Mathison and colleagues 28 reported the direct 
involvement of GATA4 in the fibrotic response post-MI 
via repression of snai1 expression, a pro-fibrotic factor. 
In agreement with these findings, our current work in Ang 
II-induced hypertension underscores the role of GATA4 in 
modulation of myocardial fibrogenesis, in addition to hy-
pertrophic remodelling.
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